Surety Medicine

Last Updated: August 19, 2019
Man in hazmat suit

​Surety medicine focuses on protecting the health of the personnel who deal with nuclear, biological or chemical materials, and on medical requirements compliance to help ensure the security of the materials.

September 2019 Surety Medicine Teleconference

DIAGNOSIS, EVALUATION AND TREATMENT OF
LABORATORY-ACQUIRED BOTULINUM TOXIN EXPOSURES

Wednesday, 25 September 2019 will bring the next monthly Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for September is “Diagnosis, Evaluation and Treatment of Laboratory-Acquired Botulinum Toxin Exposures.”  The presenter will be the Competent Medical Authority at a clinic supporting an Army research facility.

To request additional information, email the Army Public Health Center Surety Medicine Program at: usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil.


      SCHEDULE OF UPCOMING SURETY MEDICINE TELECONFERENCES 

                                                                    (subject to change):

16 OCT 2019          Vision Conservation and Readiness:  The CMA Perspective
20 NOV 2019       The Behavioral Health Specialist and the PRP
18 DEC 2019          Red Blood Cell Cholinesterase Monitoring
15 JAN 2020          Pregnancy and the PRP:  Assessing Workplace Hazards
19 FEB 2020          Case Studies in Surety Medicine
18 MAR 2020        Respirator Clearance and PPE Assessments:  The Role of Use Testing
15 APR 2020         Obstructive Sleep Apnea: Diagnosis, Treatment and PRP Compliance
20 MAY 2020       Screening for Active Tuberculosis or LTBI
17 JUN 2020          Key Stakeholders in ASAP and SUDCC: Developing a CMA Alliance
15 JUL 2020           Diagnosis and Treatment of Laboratory-Acquired Tularemia Infection
19 AUG 2020         Regulatory Updates: CPRP, BPRP, and NPRP
23 SEP 2020         Opioids and the PRP: What Every CMA Should Know


--ALERT--

Auto-Injector Shelf Life Extension: 

       NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote(R) combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labeled expiration dates, some are now extended to 2022. 

Previously extended DuoDote(R) Nerve Agent Autoinjector Kit Lots 9AE306, 9AE307, 9AE356, 9AE545, 9AE548, 9AE636 and 9AE645 all expired on or before 30 June 2019.  Lot 9AE835 expires 30 September 2019, and lots 0AE158 and 0AE159 reach their extended expiration date 31 December 2019. Check any auto-injector medication stores you have.  Select the link below for additional information.

Complete FDA information related to the auto-injector shelf life extension program can be found at this  FDA Drug Safety Page.

Information on this page also includes the latest updates on shelf life extensions for the AtroPen(R) (atropine), CANA (diazepam), morphine sulfate, and pralidoxime chloride auto-injectors, with dates listed.